LOXO
+$5.6K
1,541 sh @ $4
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD, EVP & Pres., Lilly Oncology, EVP & Pres., Loxo@Lilly, EVP and CEO Loxo@Lilly, SVP, CEO LoxoONC, Pres LlyONC, Chief Operating Officer, Chief Business Officer · SEC CIK 1661254Advertisement
Buy track record
How this insider's open-market purchases have performed100%
of buys now in profit
1 up · 0 down
Avg return since buy+72.8%
Median return+72.8%
Best trade+72.8%
Worst trade+72.8%
Buys scored1
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+13.5%
100% won · 1 trade
After 3 months
+55.2%
100% won · 1 trade
After 6 months
+58.3%
100% won · 1 trade
After 12 months
—
not elapsed yet
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | LLY | $647 | $647.4K | +5.1% | +13.5% | +55.2% | +58.3% | — | +72.8% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 1 scored trade, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$647.4K
1 trades
Open-market sells
$11.77M
138 trades
Net flow
−$11.12M
Net selling
Total filings
192
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstLOXO
−$55.6K
300 sh @ $185
LOXO
−$37.2K
200 sh @ $186
LOXO
−$120.1K
641 sh @ $187
LOXO
−$37.6K
200 sh @ $188
Advertisement
LOXO
−$18.9K
100 sh @ $189
LOXO
−$19.2K
100 sh @ $192
LOXO
+$43.8K
12,000 sh @ $4
LOXO
+$5.6K
1,541 sh @ $4
LOXO
−$204.2K
1,141 sh @ $179
LOXO
−$36K
200 sh @ $180
LOXO
−$36.2K
200 sh @ $181
LOXO
+$5.6K
1,541 sh @ $4
LOXO
−$152.6K
865 sh @ $176
LOXO
−$102.2K
576 sh @ $177
LOXO
−$17.8K
100 sh @ $178
LOXO
+$5.6K
1,541 sh @ $4
LOXO
−$26.7K
200 sh @ $133
LOXO
−$40.7K
300 sh @ $136
LOXO
−$116.4K
841 sh @ $138
LOXO
−$27.8K
200 sh @ $139
LOXO
+$5.6K
1,541 sh @ $4
LOXO
−$32.4K
241 sh @ $134
LOXO
−$82.5K
600 sh @ $137
LOXO
−$95.8K
691 sh @ $139
LOXO
−$1.3K
9 sh @ $139
LOXO
+$5.6K
1,541 sh @ $4
LOXO
−$38.6K
300 sh @ $129
LOXO
−$12.9K
100 sh @ $129
LOXO
−$78.6K
600 sh @ $131
Frequently asked questions
How is Van Naarden Jacob's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from Van Naarden Jacob's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.